NCT05640596

Brief Summary

Use of antenatal corticosteroids therapy has increased since the 2000s. The benefits of such a therapy on premature newborns are scientifically and internationally recognized. Nevertheless, few studies have been conducted to investigate the impact of this antenatal corticosteroid therapy on full-term newborns (\> 36 weeks' gestation). The aim of this study is to compare the birth parameters of full-term newborns exposed or not to antenatal corticosteroid therapy.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
363

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 12, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 25, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 7, 2022

Completed
Last Updated

December 12, 2022

Status Verified

December 1, 2022

Enrollment Period

7 years

First QC Date

July 12, 2022

Last Update Submit

December 8, 2022

Conditions

Keywords

Antenatal corticosteroid therapynewborngrowth

Outcome Measures

Primary Outcomes (1)

  • Evaluate the impact of an antenatal corticosteroid therapy on head growth.

    head circumference

    Birth

Secondary Outcomes (7)

  • Evaluate the impact of an antenatal corticosteroid therapy on fetal weight

    Birth

  • Evaluate the impact of an antenatal corticosteroid therapy on fetal growth

    birth

  • Evaluate the impact of an antenatal corticosteroid therapy on neonatal adaptation : APGAR score for each patient

    birth

  • Evaluate the impact of an antenatal corticosteroid therapy on risk of hypoglycemia : number of patients with neonatal hypoglycémia

    first 5 days

  • Evaluate the impact of an antenatal corticosteroid therapy on risk of hypocalcemia : number of patients with hypoglycemia

    first 5 days

  • +2 more secondary outcomes

Study Arms (2)

exposed group (121 patients)

Extrated from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who received at least one course of betamethasone before 34 weeks of amenorrhea for a threat of preterm delivery. Exposure to an antenatal corticosteroid therapy was defined as the administration of at least one course of betamethasone (i.e. two doses of 12 mg, 24 hours apart). in intramuscular, before 34 weeks of amenorrhea, for a threat of premature delivery.

Drug: Betamethasone

nonexposed group (242 patients)

came from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who who had not been exposed to antenatal steroid therapy. Two controls were selected for a case, appaired on the month and year of birth and on the sex of the case patient.

Interventions

exposed group (121 patients)

Eligibility Criteria

AgeUp to 12 Months
Sexall
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

All children included in the study were born at the Regional Maternity Hospital of Nancy between January 1, 2014 and December 31, 2020. One hundred and twenty-one of them were exposed during pregnancy to antenatal corticosteroids therapy and constitute the exposed arm, whereas 242 were not and constitute the non-exposed arm.

You may qualify if:

  • all children exposed to an antenatal corticosteroid therapy before 34 weeks of amenorrhea because of a threat of premature delivery
  • only full-term newborns

You may not qualify if:

  • all children exposed to an antenatal corticosteroid therapy before 34 weeks of amenorrhea for other reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Best C, Hascoet JM, Jeanbert E, Morel O, Baumann C, Renard E. Impact of corticosteroid exposure on preterm labor in neonates eventually born at term. J Perinatol. 2024 Feb;44(2):195-202. doi: 10.1038/s41372-023-01831-0. Epub 2023 Dec 1.

MeSH Terms

Interventions

Betamethasone

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

July 12, 2022

First Posted

December 7, 2022

Study Start

January 1, 2014

Primary Completion

December 31, 2020

Study Completion

November 25, 2022

Last Updated

December 12, 2022

Record last verified: 2022-12